SMMT

Summit Therapeutics' stock price has been impacted by several key events in the past six months. On May 1, 2026, the stock price was $16.11, with a 52-week range between $13.83 and $30.98. The stock experienced a significant drop of 24.91% following the release of its first-quarter financial results due to widening non-GAAP net losses, rising expenses, and a lack of immediate clinical catalysts. Analysts have adjusted price targets, with H.C. Wainwright lowering its target to $23 from $30 in early May 2026. Despite recent declines, the stock has shown a strong multi-year return.